Weed Inc(OTCMKTS:BUDZ) has been on the move in recent weeks as the Company reports on their acquisition of property in La Veta, CO., for development of its Cannabis genomic research facility which has begun its 5-Year, $15+ million Cannabis Genomic Study to complete a global genomic classification of the Cannabis plant genus.
BUDZ operates in the booming MJ sector that continues to grow; according to Forbes North American marijuana sales grew by an unprecedented 30% in 2016 to $6.7 billion as the legal market expands in the U.S. and Canada, according to a new report by Arcview Market Research. North American sales are projected to top $20.2 billion by 2021 assuming a compound annual growth rate of 25%. The report includes Canada for the first time as it moves towards implementing legal adult use marijuana.
Weed Inc(OTCMKTS:BUDZ) bills itself as a USA-based alternative reporting public company. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand. WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. subsidiaries in foreign locations.
WEED operates a wholly-owned subsidiary Sangre AT, LLC which is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. Sangre AgroTech’s world-respected team provides decades of expertise and innovation in the fields of genetics, plant biology, plant pathology, phytoecology, and sustainable and environmentally sound agricultural practices. Using annotated genomic data and newly generated phenotypic data, Sangre AgroTech will identify and isolate regions of the genome related to growth, synthesis of desired molecules, drought and pest resistance. This complex data set will be utilized in a breeding program to generate and establish new hybrid cultivars which exemplify the traits desired by the medical community.
To Find out the inside Scoop on BUDZ Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
In July Sangre Agrotech completed their acquisition of property in La Veta, CO., as stated in our last press release for development of its Cannabis genomic research facility, The Sangre Bioscience Center. La Veta, located in southern Colorado’s Spanish Peaks region, is the new home for Sangre AT, LLC (dba “Sangre AgroTech”), the Company’s wholly-owned subsidiary. Sangre AgroTech has begun its 5-Year, $15+ million Cannabis Genomic Study to complete a global genomic classification of the Cannabis plant genus.
The site includes a 10,000+ sq. ft. building that will house the genomic research facility, a 4,000+ square foot building for plant product analytics and plant product extraction, a 3,500 sq. ft. corporate office center, and 25 RV slots with full water and electric, which the company plans to convert into a series of small research pods. This acquisition provides WEEDS’ Sangre AgroTech with the opportunity to expand its research mission through the construction of additional research laboratories and cloning facilities.
Glenn E. Martin, CEO of WEED, Inc., stated, “The purchase of the Le Veta property is an important step to allow Sangre AgroTech to have a state-of-the-art facility to conduct its Cannabis genomic research and is a building block for WEED’s larger, global strategy of creating a vertically-integrated cannabis business. WEED is also happy to be a part of the greater La Veta community and plans to make a positive impact in the surrounding area and the State of Colorado in the years to come.”
we have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $138 million market valuation BUDZ has $475,000 in the treasury, minimal assets and no revenues to date. BUDZ is an exciting story deceloping in small caps; the Company is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization whos wholly-owned subsidiary Sangre AT, LLC recently acquired a research facility and has begun its 5-Year, $15+ million Cannabis Genomic Study to complete a global genomic classification of the Cannabis plant genus. We will be updating on BUDZ when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BUDZ.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in BUDZ either long or short and we have not been compensated for this article.